公开(公告)号：US09932311B2

公开(公告)日：2018-04-03

申请号：US15023124

申请日：2014-09-30

Applicant: Merck Sharp & Dohme Corp.

Inventor： Tesfaye Biftu ,  Purakkattle Biju ,  Steven L. Colletti ,  Mingxiang Cui ,  William K. Hagmann ,  Bin Hu ,  Hubert Josien ,  Nam Fung Kar ,  Anilkumar Nair ,  Ravi Nargund ,  Donald M. Sperbeck ,  Cheng Zhu

IPC: C07D221/16 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  A61K31/435 ,  A61K31/444 ,  A61K45/06

CPC classification number: C07D221/16 ,  A61K31/435 ,  A61K31/444 ,  A61K45/06 ,  C07D401/12 ,  C07D405/12

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

公开(公告)号：US20160207887A1

公开(公告)日：2016-07-21

申请号：US15023124

申请日：2014-09-30

Applicant: MERCK SHARP & DOHME CORP.

Inventor： Tesfaye Biftu ,  Purakkattle Biju ,  Steven L. Colletti ,  Mingxiang Cui ,  William K. Hagmann ,  Bin Hu ,  Hubert Josien ,  Nam Fung Kar ,  Anilkumar Nair ,  Ravi Nargund ,  Donald M. Sperbeck ,  Cheng Zhu

IPC: C07D221/16 ,  A61K45/06 ,  C07D405/12 ,  A61K31/444 ,  A61K31/435 ,  C07D401/12

CPC classification number: C07D221/16 ,  A61K31/435 ,  A61K31/444 ,  A61K45/06 ,  C07D401/12 ,  C07D405/12

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslip idemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Abstract translation: 结构式（I）的新型化合物及其药学上可接受的盐是G蛋白偶联受体40（GPR40）的激动剂，可用于治疗，预防和抑制G蛋白偶联受体 受体40.本发明的化合物可用于治疗2型糖尿病，以及通常与该疾病相关的病症，包括肥胖症和脂质疾病，例如混合型或糖尿病型血脂异常，高脂血症，高胆固醇血症， 和高甘油三酯血症。

公开(公告)号：US10519115B2

公开(公告)日：2019-12-31

申请号：US15032191

申请日：2014-11-10

Applicant: Merck Sharp & Dohme Corp.

Inventor： Tesfaye Biftu ,  Purakkattle Biju ,  Steven L. Colletti ,  Qun Dang ,  Pawan Dhondi ,  Candido Gude ,  Hubert Josien ,  Nam Fung Kar ,  Anilkumar G. Nair ,  Ravi P. Nargund ,  De-Yi Yang ,  Cheng Zhu

IPC: C07D221/16 ,  A61K31/435 ,  C07D401/12 ,  C07D487/04 ,  C07D487/10 ,  A61K9/20 ,  A61K31/444 ,  A61K31/4545 ,  A61K45/06

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

公开(公告)号：US20160257652A1

公开(公告)日：2016-09-08

申请号：US15032191

申请日：2014-11-10

Applicant: MERCK SHARP & DOHME CORP.

Inventor： Tesfaye Biftu ,  Purakkattle Biju ,  Steven L. Colletti ,  Qun Dang ,  Pawan Dhondi ,  Candido Gude ,  Hubert Josien ,  Nam Fung Kar ,  Anilkumar G. Nair ,  Ravi P. Nargund ,  De-Yi Yang ,  Cheng Zhu

IPC: C07D221/16 ,  A61K9/20 ,  A61K31/435 ,  A61K31/444 ,  C07D401/12 ,  A61K31/4545 ,  C07D487/04 ,  A61K45/06 ,  C07D487/10

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.